Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

Simple external cues, such as lines on the floor, can help Parkinson’s patients focus their efforts and overcome the ...

Managing patients with Parkinson's disease should be viewed as part of a hospital CMO's responsibility for patient safety and ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

除了血液检查可以检查痴呆外，还可通过全面的血液检测，排除其他疾病所导致的认知功能下降或痴呆。如帕金森病患者合并有血液的改变，最常见的病因可能是维生素B12的缺乏，这会影响患者的认知能力。部分患者还会出现贫血，血常规的检测也非常重要；部分患者会合并甲减 ...

AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...

Parkinson’s disease is a progressive neurological disorder in which ongoing changes in the brain affect and interfere with ...

Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...

A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for ...

“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.